AbolerIS Pharma Takes a Major Step in Rheumatoid Arthritis Treatment with First Patient Dosed in Phase 1 Study AbolerIS Pharma marks a significant milestone in autoimmune treatment with the first patient dosed in a Phase 1 study of ABO21009 for rheumatoid arthritis.

AbolerIS Pharma Takes a Major Step in Rheumatoid Arthritis Treatment with First Patient Dosed in Phase 1 Study #Belgium #rheumatoid_arthritis #ABO21009 #Gosselies #AbolerIS

AbolerIS Pharma Launches Phase 1 Study for Novel Rheumatoid Arthritis Treatment AbolerIS Pharma has initiated a Phase 1 trial of ABO21009, a new anti-CD45RC antibody aimed at treating rheumatoid arthritis, with promising implications for future therapies.

AbolerIS Pharma Launches Phase 1 Study for Novel Rheumatoid Arthritis Treatment #Belgium #rheumatoid_arthritis #ABO21009 #Gosselies #AbolerIS